Epigallocatechin-3-gallate ( DrugBank: Epigallocatechin, Epigallocatechin-3-gallate )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
8ハンチントン病1
28全身性アミロイドーシス1
85特発性間質性肺炎2

8. ハンチントン病


臨床試験数 : 242 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01357681
(ClinicalTrials.gov)
September 201119/5/2011Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease The ETON-Study - A Randomized, Double-blind, Stratified, Placebo-controlled Prospective Investigator Initiated Multicenter Trial -Huntington DiseaseDrug: (2)-epigallocatechin-3-gallate (EGCG);Drug: PlaceboCharite University, Berlin, GermanyNULLCompleted18 YearsN/ABoth54Phase 2Germany

28. 全身性アミロイドーシス


臨床試験数 : 267 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02015312
(ClinicalTrials.gov)
April 201318/11/2013A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)Light Chain (AL) Amyloidosis;Cardiac InvolvementDrug: Epigallocatechin-3-gallate (EGCG);Drug: PlaceboFlorian MichelGerman Federal Ministry of Education and ResearchCompleted18 YearsN/AAll38Phase 2Germany

85. 特発性間質性肺炎


臨床試験数 : 627 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05195918
(ClinicalTrials.gov)
March 1, 20232/12/2021Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF PatientsDose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients With Idiopathic Pulmonary Fibrosis (IPF) Evaluating Safety, PK Interactions With Standard of Care Drugs, and Biomarkers of Drug EffectIdiopathic Pulmonary FibrosisCombination Product: EGCG 300 mg + Nintedanib;Combination Product: EGCG 300 mg + Pirfenidone;Combination Product: Placebo 2 capsules + Nintedanib or Pirfenidone;Combination Product: EGCG 600 mg + Nintedanib;Combination Product: EGCG 600 mg + Pirfenidone;Combination Product: Placebo 4 capsules + Nintedanib or PirfenidoneHal ChapmanUniversity of Michigan;Cornell University;Massachusetts General Hospital;Temple University;University of WashingtonNot yet recruiting40 Years85 YearsAll50Phase 1United States
2NCT03928847
(ClinicalTrials.gov)
December 1, 201718/4/2019Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.Idiopathic Pulmonary FibrosisDrug: Epigallocatechin-3-gallate (EGCG)Hal ChapmanNational Heart, Lung, and Blood Institute (NHLBI)Completed40 Years70 YearsAll35Early Phase 1United States